InMed Pharmaceuticals Inc.
Jefferies initiated coverage on Mentari Therapeutics (NASDAQ:MTRI) with a buy rating and a $30.00 price target, citing its migraine prevention drug pipeline. The stock trades at $16, 31% below its 52-week high. The company expects Phase I data for MT-001 and MT-002 in 2027. MTRI has $450 million in cash, providing runway into 2029.
ADAR1 Capital Management, a 10% owner of InMed Pharmaceuticals (INM), bought 2,640 shares at an average price of $13.10, totaling $34.6K on Nov 5, 2026. Post-transaction, they held 98,297 shares indirectly. The purchase occurred after a 1-for-10 reverse stock split and before a merger that renamed the company Mentari Therapeutics (MTRI).
ADAR1 Capital Management, LLC purchased 2,640 indirectly-held shares of InMed Pharmaceuticals Inc. (INM) at $13.10 on 2026-11-05. Filed jointly with Schneeberger Daniel (10% owner).
Over the past 7 days, AlphAI's AI scored 11 news stories mentioning MTRI (InMed Pharmaceuticals Inc.). Coverage has skewed bullish: 4 bullish, 6 neutral, and 1 bearish.
Recent MTRI coverage spans financial news, corporate actions and mergers & acquisitions.
In the last 30 days, MTRI insiders filed 7 SEC Form 4 transactions — 7 purchases ($49K) and no sales. The most active reporter was ADAR1 Capital Management, LLC with 7 filings.
Analyst buy rating and elevated price target likely drive buying interest.
ADAR1 Capital Management, a 10% owner of InMed Pharmaceuticals (INM), bought 2,640 shares at an average price of $13.10, totaling $34.6K on Nov 5, 2026. Post-transaction, they held 98,297 shares indirectly. The purchase occurred after a 1-for-10 reverse stock split and before a merger that renamed the company Mentari Therapeutics (MTRI).
ADAR1 Capital Management, LLC purchased 2,640 indirectly-held shares of InMed Pharmaceuticals Inc. (INM) at $13.10 on 2026-11-05. Filed jointly with Schneeberger Daniel (10% owner).
Guggenheim started coverage of InMed Pharmaceuticals with a Buy rating and a $42 price target, according to the firm.
InMed Pharmaceuticals Inc. (INM) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Mentari Therapeutics Announces Closing of Merger with InMed Pharmaceuticals and Previously Announced $490 Million Financing Mentari is advancing a robust pipeline of biologics for the prevention of migraine, including MT-001 and MT-002, which target clinically valida
AlphAI scores every news story that mentions MTRI with an AI model for sentiment and relevance, and aggregates insider trades from InMed Pharmaceuticals Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Jefferies initiated coverage on Mentari Therapeutics (NASDAQ:MTRI) with a buy rating and a $30.00 price target, citing its migraine prevention drug pipeline. The stock trades at $16, 31% below its 52-week high. The company expects Phase I data for MT-001 and MT-002 in 2027. MTRI has $450 million in cash, providing runway into 2029.
ADAR1 Capital Management, a 10% owner of InMed Pharmaceuticals (INM), bought 2,640 shares at an average price of $13.10, totaling $34.6K on Nov 5, 2026. Post-transaction, they held 98,297 shares indirectly. The purchase occurred after a 1-for-10 reverse stock split and before a merger that renamed the company Mentari Therapeutics (MTRI).
ADAR1 Capital Management, LLC purchased 2,640 indirectly-held shares of InMed Pharmaceuticals Inc. (INM) at $13.10 on 2026-11-05. Filed jointly with Schneeberger Daniel (10% owner).
Guggenheim started coverage of InMed Pharmaceuticals with a Buy rating and a $42 price target, according to the firm.
InMed Pharmaceuticals Inc. (INM) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Mentari Therapeutics Announces Closing of Merger with InMed Pharmaceuticals and Previously Announced $490 Million Financing Mentari is advancing a robust pipeline of biologics for the prevention of migraine, including MT-001 and MT-002, which target clinically valida
Mentari Therapeutics, a biotech firm, raised $490 million before merging with InMed. Shares will trade on Nasdaq under 'MTRI' starting November 9, 2026. Mentari focuses on migraine therapies, with lead programs MT-001 and MT-002. The company issued contingent value rights to shareholders before the merger.
InMed Pharmaceuticals Inc. (INM) filed an SEC Form 8-K — Regulation FD Disclosure. NASDAQ: INM 1800 - 510 West Georgia St. Vancouver, BC, Canada V6B 0M3 Tel: +1.604.669.7207 Email: info@inmedpharma.com www.inmedpharma.com InMed Announces Results of 2026 Annual General and Special Meeting, Approval of Corporate Name Change and Completion of Share Consolidation V
InMed Pharmaceuticals Inc. (INM) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Exhibit 99.1 NASDAQ: INM 1800 – 510 West Georgia St. Vancouver, BC, Canada V6B 0M3 Tel: +1.604.669.7207 Email: info@inmedpharma.com www.inmedpharma.com InMed Announces Results of 2026 Annual General and Special Meeting, Approval of Corporate Name Change and Completion of Share Co
InMed Pharmaceuticals (NASDAQ: INM), now Mentari Therapeutics, completed its annual meeting. Shareholders approved all proposals, including a name change, share consolidation, and various corporate actions. The company's shares will trade on Nasdaq under the same symbol but with a new CUSIP and ISIN. The consolidation reduced outstanding shares from 5.49 million to approximately 549,374.
InMed Pharmaceuticals Inc. (INM) filed an SEC Form 8-K — Regulation FD Disclosure. InMed Reports First Quarter Fiscal 2027 Financial Results and Provides Corporate Update Vancouver, British Columbia--(Newsfile Corp. - November 3, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipelin
